Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Atea Pharmaceuticals (AVIR) stock in plain English

Free brief · no signupStart here
AVIRPublished Nov 19, 2026
Atea Pharmaceuticals Inc
Healthcare · Biotechnology
Discovers and tests oral antiviral medicines aimed at treating hepatitis C and respiratory viral infections.
Assets:
Bemnifosbuvir pipelineleads clinical testing in combination with ruzasvir for hepatitis C
Boston headquartersoperates research and executive offices in Massachusetts
Core teamemploys around sixty people to manage clinical development
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

90
OPS ScoreOperating finances
Latest quote
-1.50%$3.93
$315.59M
n/a
-

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was AVIR. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Atea Pharmaceuticals (AVIR) do?

Atea Pharmaceuticals Inc (AVIR) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Discovers and tests oral antiviral medicines aimed at treating hepatitis C and respiratory viral infections. Develops oral antiviral therapies targeting severe viral infections using an internal purine nucleotide prodrug. It is worth $315.59M on the market.

Market cap
$315.59M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

AVIR’s flags, in plain English

Each flag is a number from Atea Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 20.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Thinly Traded

Thinly traded, about 287 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.

Questions about AVIR

How big is Atea Pharmaceuticals?

Atea Pharmaceuticals’ market cap is $315.59M: what all of its shares are worth together at today’s price.

What could go wrong with AVIR?

The business relies on clinical trial results for bemnifosbuvir and lacks approved commercial products generating sales. That is one risk on Atea Pharmaceuticals’ card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Atea Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AVIR’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card